China Regenerative Medicine International Limited (HKG:8158)

HKG:8158 Revenue

China Regenerative Medicine International had revenue of 41.73M HKD in the half year ending June 30, 2026, a decrease of -30.19%. This brings the company's total for the last twelve months to 86.40M, up 48.39% year-over-year. In the year 2025, China Regenerative Medicine International had annual revenue of 72.06M, down -20.48%. That makes China Regenerative Medicine International the 36,914th largest company in the world by revenue and 2,240th in Hong Kong.

• Revenue (ttm): 86.40M
• Revenue Growth: +48.39%
• P/S Ratio: 0.81
• Revenue / Employee: 2.62M
• Employees: 33
• Market Cap: 69.98M

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Aesthetic Medical and Beauty Services 64.04M 88.9%
• Medical Services 8.02M 11.1%

By Geography

Chart

• Hong Kong 66.09M 91.7%
• The PRC 5.96M 8.3%

Fiscal year ended Dec 31, 2025 See the full HKG:8158 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	72.06M	-18.56M	-20.48%
Dec 31, 2024	90.62M	21.13M	30.41%
Dec 31, 2023	69.49M	27.95M	67.29%
Dec 31, 2022	41.54M	-241.36M	-85.32%
Dec 31, 2021	282.90M	100.76M	55.32%

Data Source: S&P Global Market Intelligence Last updated: Aug 21, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Nov 1, 2026

Data Sources Report a data error